Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 20
4 104
3 141
2 36
1 21
Curative setting
A 41
C 3
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 2
Breast Cancer 34
Central Nervous System Malignancies 1
Endocrine Tumours 20
Gastrointestinal Cancers 59
Genitourinary Cancers 54
Gynaecological Malignancies 32
Head and neck cancer 9
Melanoma 21
RET fusion-positive tumours 1
Refractory NTRK fusion–positive cancers 2
Sarcoma 9
Skin Cancers 6
TMB-H solid tumours 1
Thoracic Malignancies 70
dMMR/MSI-H solid tumours 1
Curative setting
Brain Tumours 0
Breast Cancer 7
Central Nervous System Malignancies 1
Endocrine Tumours 0
Gastrointestinal Cancers 15
Genitourinary Cancers 3
Gynaecological Malignancies 0
Head and neck cancer 0
Melanoma 11
RET fusion-positive tumours 0
Refractory NTRK fusion–positive cancers 0
Sarcoma 2
Skin Cancers 1
TMB-H solid tumours 0
Thoracic Malignancies 4
dMMR/MSI-H solid tumours 0

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in “orphan diseases” and for diseases with “high unmet need” when primary outcome is PFS or ORR.
Quality of Life Checklist To evaluate ESMO-MCBS score adjustments based on quality of life

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Trastuzumab deruxtecan - Either irinitecan or paclitaxel (Phase II) Treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma in patients who have received a prior trastuzumab-based regimen Gastrointestinal Cancers Gastric or gastroesophageal junction adenocarcinoma HER2+ DESTINIY-Gastric01
    4

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Trabectedin - Dacarbazine Treatment for patients with advanced soft-issue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients Sarcoma Soft tissue - Liposarcoma or leiomyosarcoma - -
    2

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      4
    Niraparib - Placebo Maintenance treatment for high grade ovarian, fallopian tube or peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based ChT Gynaecological Malignancies Ovarian, fallopian tubes and peritoneum cancer HRD+ PRIMA/ENGOT-OV26/COG-3012
    3

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Olaparib Bevacizumab Placebo plus bevacizumab Maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability Gynaecological Malignancies High-grade epithelial ovarian, fallopian tube or primary peritoneal cancer BRCA mutation PAOLA-1
    3

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Olaparib Bevacizumab Placebo plus bevacizumab Maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability Gynaecological Malignancies High-grade epithelial ovarian, fallopian tube or primary peritoneal cancer HRD+ BRCA-WT PAOLA-1
    3

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Avelumab - Single arm (Phase II) Adult patients with metastatic Merkel cell carcinoma (MCC) Skin Cancers Merkel cell carcinoma - JAVELIN Merkel 200 (Part A - pretreated patients)
    4

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Nivo/Ipi (nivolumab and ipilimumab) - ChT with cisplatin or carboplatin plus pemetrexed First-line treatment for adult patients with unresectable malignant pleural mesothelioma. Thoracic Malignancies Pleural mesothelioma - CheckMate743
    3

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Ramucirumab Erlotinib Placebo First-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations Thoracic Malignancies Non-small-cell Lung Cancer EGFR exon 19 deletions or exon 21 (L858R) mutation RELAY
    3

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Nivo/Ipi (nivolumab and ipilimumab) - Single arm (Phase II) Treatment of patients who have previously been treated with sorafenib Gastrointestinal Cancers Hepatobiliary Cancers - Hepatocellular Carcinoma - CheckMate 040
    3

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Tazemetostat - Single arm (Phase II) Treatment for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection Sarcoma Epithelioid INI1-negative EZH-202
    1

    PRELIMINARY SCORE

    • OS
      8

    ADJUSTMENTS

    FINAL SCORE

    • F1
      5

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.